Post-exposure treatment of Ebola virus disease in Guinea pigs using EBOTAb, an ovine antibody-based therapeutic

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dowall, Stuart D ^a   Bosworth, Andrew ^a   Rayner, Emma ^a   Taylor, Irene ^a   Landon, John ^a   Cameron, Ian ^b   Coxon, Ruth ^b   Al Abdulla, Ibrahim ^b   Graham, Victoria A ^a   Hall, Graham ^a   Kobinger, Gary ^c,d   Hewson, Roger ^a   Carroll, Miles W ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Newcastle Emlyn   (United Kingdom)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS RNA; ZMAPP;

ANIMAL; ANTIBODY SPECIFICITY; BLOOD; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENETICS; GUINEA PIG; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY; POST EXPOSURE PROPHYLAXIS; SHEEP; SPLEEN; SURVIVAL ANALYSIS; VIROLOGY; VIRUS GENOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; EBOLAVIRUS; GENOME, VIRAL; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; LIVER; POST-EXPOSURE PROPHYLAXIS; RNA, VIRAL; SHEEP; SPLEEN; SURVIVAL ANALYSIS;

EID: 84979929572     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30497     Document Type: Article

References (60)

1. Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. The New England journal of medicine 371, 1418-1425, doi: 10.1056/NEJMoa1404505 (2014).
2. WHO. Ebola haemorrhagic fever in Zaire, 1976. Bulletin of the World Health Organization 56, 271-293 (1978).
3. Gulland, A. First Ebola treatment is approved by WHO. Bmj 349, g5539, doi: 10.1136/bmj.g5539 (2014).
4. Kreil, T. R. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerging infectious diseases 21, 521-523, doi: 10.3201/eid2103.141838 (2015).
5. Friedrich, B. M. et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4, 1619-1650, doi: 10.3390/v4091619 (2012).
6. Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 1953-1958, doi: 10.1016/S0140-6736(03)15012-X (2003).
7. Hensley, L. E. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. The Journal of infectious diseases 196 Suppl 2, S390-S399, doi: 10.1086/520598 (2007).
8. Warren, T. K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature medicine 16, 991-994, doi: 10.1038/nm.2202 (2010).
9. Geisbert, T. W. et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. The Journal of infectious diseases 193, 1650-1657, doi: 10.1086/504267 (2006).
10. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896-1905, doi: 10.1016/S0140-6736(10)60357-1 (2010).
11. Michelow, I. C. et al. High-dose mannose-binding lectin therapy for Ebola virus infection. The Journal of infectious diseases 203, 175-179, doi: 10.1093/infdis/jiq025 (2011).
12. Warren, T. K. et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrobial agents and chemotherapy 54, 2152-2159, doi: 10.1128/AAC.01315-09 (2010).
13. Aman, M. J. et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral research 83, 245-251, doi: 10.1016/j.antiviral.2009.06.001 (2009).
14. Wong, G., Qiu, X., Olinger, G. G., Kobinger, G. P. Post-exposure therapy of filovirus infections. Trends in microbiology 22, 456-463, doi: 10.1016/j.tim.2014.04.002 (2014).
15. Feldmann, H. et al. Effective post-exposure treatment of Ebola infection. PLoS pathogens 3, e2, doi: 10.1371/journal.ppat.0030002 (2007).
16. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53, doi: 10.1038/nature13777 (2014).
17. Qiu, X. et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. Journal of virology 87, 7754-7757, doi: 10.1128/JVI.00173-13 (2013).
18. Davidson, E. et al. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. Journal of virology 89, 10982-10992, doi: 10.1128/JVI.01490-15 (2015).
19. Alfson, K. J., Worwa, G., Carrion, R., Jr., Griffiths, A. Determination of the Spontaneous Mutation Frequency of Ebola virus and Exploitation of this Therapeutically. Journal of virology, doi: 10.1128/JVI.02701-15 (2015).
20. Dowall, S. D. et al. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. The Journal of infectious diseases, doi: 10.1093/infdis/jiv565 (2015).
21. Habib, A. G. Public health aspects of snakebite care in West Africa: perspectives from Nigeria. The journal of venomous animals and toxins including tropical diseases 19, 27, doi: 10.1186/1678-9199-19-27 (2013).
22. Kugelman, J. R. et al. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell reports 12, 2111-2120, doi: 10.1016/j.celrep.2015.08.038 (2015).
23. White, J. M., Schornberg, K. L. A new player in the puzzle of filovirus entry. Nature reviews. Microbiology 10, 317-322, doi: 10.1038/nrmicro2764 (2012).
24. Gonzalez-Gonzalez, E. et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Critical reviews in biotechnology, 1-16, doi: 10.3109/07388551.2015.1114465 (2015).
25. Connolly, B. M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of infectious diseases 179 Suppl 1, S203-S217, doi: 10.1086/514305 (1999).
26. Vogt, F. et al. Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 20, doi: 10.2807/1560-7917.ES.2015.20.50.30097 (2015).
27. Qiu, X. et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS neglected tropical diseases 6, e1575, doi: 10.1371/journal.pntd.0001575 (2012).
28. Olinger, G. G., Jr. et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America 109, 18030-18035, doi: 10.1073/pnas.1213709109 (2012).
29. Qiu, X., Kobinger, G. P. Antibody therapy for Ebola: is the tide turning around? Human vaccines & immunotherapeutics 10, 964-967 (2014).
30. Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Scientific reports 4, 6881, doi: 10.1038/srep06881 (2014).
31. Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science translational medicine 4, 138ra181, doi: 10.1126/scitranslmed.3003876 (2012).
32. Varkey, J. B. et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. The New England journal of medicine 372, 2423-2427, doi: 10.1056/NEJMoa1500306 (2015).
33. MacIntyre, C. R., Chughtai, A. A. Recurrence and reinfection-a new paradigm for the management of Ebola virus disease. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 43, 58-61, doi: 10.1016/j.ijid.2015.12.011 (2015).
34. Kelley, B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 1, 443-452 (2009).
35. McCarthy, M. U. S. signs contract with ZMapp maker to accelerate development of the Ebola drug. Bmj 349, g5488, doi: 10.1136/bmj.g5488 (2014).
36. Fulton, A., Lai, H., Chen, Q., Zhang, C. Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana. Journal of chromatography. A 1389, 128-132, doi: 10.1016/j.chroma.2015.02.013 (2015).
37. Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proceedings of the National Academy of Sciences of the United States of America 108, 20690-20694, doi: 10.1073/pnas.1108360108 (2011).
38. Feldmann, H., Jones, S., Klenk, H. D., Schnittler, H. J. Ebola virus: from discovery to vaccine. Nature reviews. Immunology 3, 677-685, doi: 10.1038/nri1154 (2003).
39. Wong, G. et al. Ebola virus transmission in guinea pigs. Journal of virology 89, 1314-1323, doi: 10.1128/JVI.02836-14 (2015).
40. O'Dempsey, T., Khan, S. H., Bausch, D. G. Rethinking the discharge policy for Ebola convalescents in an accelerating epidemic. The American journal of tropical medicine and hygiene 92, 238-239, doi: 10.4269/ajtmh.14-0719 (2015).
41. Richardson, J. S. et al. Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. Journal of bioterrorism & biodefense S1, 007, doi: 10.4172/2157-2526 (2011).
42. Qiu, X. et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Science translational medicine 5, 207ra143, doi: 10.1126/scitranslmed.3006605 (2013).
43. Reddy, K. R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33, 433-438, doi: 10.1053/jhep.2001.21747 (2001).
44. Roberts, A. et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infection and immunity 80, 875-882, doi: 10.1128/IAI.05684-11 (2012).
45. Lepak, M. R., Bochenek, S. H., Bush, S. P. Severe adverse drug reaction following Crotalidae Polyvalent Immune Fab (Ovine) administration for copperhead snakebite. The Annals of pharmacotherapy 49, 145-149, doi: 10.1177/1060028014555711 (2015).
46. Mullins, M. E., Liss, D. B., Schwarz, E. S. Comment: severe anaphylactic reaction following crotalidae polyvalent immune fab (ovine) administration for copperhead snakebite. The Annals of pharmacotherapy 49, 496, doi: 10.1177/1060028015571964 (2015).
47. Geisbert, T. W., Jahrling, P. B. Exotic emerging viral diseases: progress and challenges. Nature medicine 10, S110-S121, doi: 10.1038/nm1142 (2004).
48. Bray, M., Paragas, J. Experimental therapy of filovirus infections. Antiviral research 54, 1-17 (2002).
49. Baskerville, A., Bowen, E. T., Platt, G. S., McArdell, L. B., Simpson, D. I. The pathology of experimental Ebola virus infection in monkeys. The Journal of pathology 125, 131-138, doi: 10.1002/path.1711250303 (1978).
50. Johnson, E., Jaax, N., White, J., Jahrling, P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. International journal of experimental pathology 76, 227-236 (1995).
51. Kortepeter, M. G. et al. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerging infectious diseases 14, 881-887, doi: 10.3201/eid1406.071489 (2008).
52. Formenty, P. et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. The Journal of infectious diseases 179 Suppl 1, S48-S53, doi: 10.1086/514285 (1999).
53. Emond, R. T., Evans, B., Bowen, E. T., Lloyd, G. A case of Ebola virus infection. British medical journal 2, 541-544 (1977).
54. Gunther, S. et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. The Journal of infectious diseases 204 Suppl 3, S785-S790, doi: 10.1093/infdis/jir298 (2011).
55. Weber, D. J., Fischer, W. A., Wohl, D. A., Rutala, W. A. Protecting healthcare personnel from acquiring Ebola virus disease. Infection control and hospital epidemiology 36, 1229-1232, doi: 10.1017/ice.2015.205 (2015).
56. Cenciarelli, O. et al. Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013-2015. Virus research 210, 318-326, doi: 10.1016/j.virusres.2015.09.002 (2015).
57. Kuhn, J. H. et al. Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome announcements 2, doi: 10.1128/genomeA.01178-14 (2014).
58. Dowall, S. D. et al. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome biology 15, 540, doi: 10.1186/PREACCEPT-1724277741482641 (2014).
59. Dowall, S. et al. Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral research 97, 108-111, doi: 10.1016/j. antiviral.2012.11.003 (2013).
60. Trombley, A. R. et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. The American journal of tropical medicine and hygiene 82, 954-960, doi: 10.4269/ajtmh.2010.09-0636 (2010).